The cost of Vertex Pharmaceuticals’ cystic fibrosis drug Orkambi is under the spotlight again after the health technology appraisal body, the Scottish Medicines Consortium, recommended against the routine use of the product on the National Health Service in Scotland. Its counterpart in England, NICE, has already taken the same stance.
The SMC announced today that it could not accept Orkambi (lumacaftor/ivacaftor) or another CF drug made by Vertex, Symkevi (tezacaftor/ivacaftor),...








